Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.

Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):149-156. doi: 10.1097/MEG.0000000000001263.

PMID:
30234644
2.

Training and Practices of Cannabis Dispensary Staff.

Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO.

Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.

3.

Potential of Cannabidiol for the Treatment of Viral Hepatitis.

Lowe HI, Toyang NJ, McLaughlin W.

Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118. doi: 10.4103/0974-8490.199780.

4.

Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol.

Hegde VL, Nagarkatti PS, Nagarkatti M.

PLoS One. 2011 Apr 1;6(4):e18281. doi: 10.1371/journal.pone.0018281.

5.

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G.

Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Review.

6.

Gateways to clinical trials.

Bayes M, Rabasseda X, Prous JR.

Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45.

PMID:
17520107

Supplemental Content

Loading ...
Support Center